鼻用氮卓斯汀与氟替卡松联合治疗变应性鼻炎:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、EMBASE、Cochrane和MEDLINE数据库,纳入8项随机对照试验,比较鼻用氮卓斯汀与氟替卡松复方鼻喷剂(AzeFlu)与单药或安慰剂治疗变应性鼻炎的疗效。Meta分析显示,复方治疗在降低总鼻症状评分方面优于安慰剂、氮卓斯汀单药和氟替卡松单药。作者认为当前证据支持复方鼻喷剂的疗效和优越性,并建议将其作为单药治疗未控制变应性鼻炎患者的二线治疗。
要点
- 复方鼻喷剂降低总鼻症状评分优于安慰剂(均数较基线变化-2.41)。
- 复方鼻喷剂降低总鼻症状评分优于氮卓斯汀单药(-1.40)和氟替卡松单药(-0.74)。
- 作者建议复方鼻喷剂作为单药未控制变应性鼻炎患者的二线治疗。
核心结论
- 当前证据支持鼻用氮卓斯汀与氟替卡松复方鼻喷剂在降低变应性鼻炎患者报告症状评分方面的疗效和优越性。
- 复方鼻喷剂应被考虑作为单药治疗未控制变应性鼻炎患者的二线治疗。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE、Cochrane和MEDLINE数据库,纳入使用AzeFlu鼻喷剂的随机对照试验。
- 纳入报告男女各年龄段变应性鼻炎症状缓解的随机对照试验,结果按PRISMA标准报告。
- 系统评价识别出8篇适合纳入的文章,偏倚风险总体较低。
主要发现
- 所有研究均显示,与单药治疗或安慰剂相比,复方治疗组患者报告的症状评分下降幅度更大。
- Meta分析显示复方治疗降低总鼻症状评分优于安慰剂(均数较基线变化-2.41;95%CI -2.82至-1.99;P<.001;I²=60%)。
- Meta分析显示复方治疗降低总鼻症状评分优于氮卓斯汀(均数较基线变化-1.40;95%CI -1.82至-0.98;P<.001;I²=0%)。
- Meta分析显示复方治疗降低总鼻症状评分优于氟替卡松(均数较基线变化-0.74;95%CI -1.17至-0.31;P<.001;I²=12%)。
关键数值与推荐
- 复方治疗对比安慰剂降低总鼻症状评分:均数较基线变化-2.41(95%CI -2.82至-1.99;P<.001;I²=60%)。
- 复方治疗对比氮卓斯汀降低总鼻症状评分:均数较基线变化-1.40(95%CI -1.82至-0.98;P<.001;I²=0%)。
- 复方治疗对比氟替卡松降低总鼻症状评分:均数较基线变化-0.74(95%CI -1.17至-0.31;P<.001;I²=12%)。
临床怎么用
- 作者认为,复方鼻喷剂应被考虑作为单药治疗未控制变应性鼻炎患者的二线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis. This systematic review and meta-analysis examines existing literature to determine efficacy in treating allergic rhinitis compared to monotherapy. DATA SOURCES: The PubMed, EMBASE, Cochrane, and MEDLINE databases were systematically searched for randomized controlled trials using AzeFlu nasal spray. REVIEW METHODS: Randomized, controlled trials that reported symptom relief of allergic rhinitis in males and females of all ages were included. Results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard. RESULTS: Systematic review identified 8 articles suitable for review. The risk of bias was generally low. All studies exhibited a greater decrease in patient-reported symptom scores in patients treated with combination therapy compared to monotherapy or placebo. Meta-analysis revealed superiority of combination therapy in reducing Total Nasal Symptom Score compared to placebo (mean change from baseline: -2.41; 95% confidence interval [CI], -2.82 to -1.99; P < .001; I2 = 60%), azelastine (mean change from baseline: -1.40; 95% CI, -1.82 to -0.98; P < .001; I2 = 0%), and fluticasone (mean change from baseline: -0.74; 95% CI, -1.17 to -0.31; P < .001; I2 = 12%). CONCLUSION: Current evidence supports both efficacy and superiority of combination intranasal azelastine and fluticasone in reducing patient-reported symptom scores in patients with allergic rhinitis. Combination nasal spray should be considered as second-line therapy in patients with allergic rhinitis that is not controlled with monotherapy.
引用
- Debbaneh PM, Bareiss AK, Wise SK, et al. Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2019. PMID: 30961435. doi:10.1177/0194599819841883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。